What does Infinity Bio do?
Infinity Bio develops innovative biotechnology solutions by mapping immune responses using its proprietary antibody reactome profiling technology and MIPSA platform.
How much did they raise?
The company raised $8M in a Series A funding round led by Illumina Ventures, with participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund.
What are their plans for the money?
The funds will be used to expand its commercial footprint, accelerate the development of its proprietary MIPSA platform, and launch new immune profiling services, potentially enhancing biomarker discovery and therapeutic developments.
What have they achieved so far?
Since its founding in 2023, Infinity Bio has established a 9,000 square-foot laboratory in Baltimore and developed a suite of core services including HuSIGHT, VirSIGHT, AllerSIGHT, and MuSIGHT for diverse research and clinical applications.